Finance

Lists
Why is CRBP down 7,74%?
Dive Deeper
CRBP:NASDAQ
Corbus Pharmaceuticals Holdings Inc
4,41 $
-7,74%
(-0,37) 1D
4,56 $
+3,40% (+0,15)
After hours
Closed: 14 қаз., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CRBP...
Open
4,72 $
High
4,82 $
Low
4,37 $
Mkt. cap
85,30 млн
Avg. vol.
1,21 млн
Volume
0,00
52-wk high
20,56 $
52-wk low
4,37 $
EPS
-6,17 $
Beta
2,63
Shares outstanding
19,34 млн
No. of employees
36
Open
4,72 $
High
4,82 $
Low
4,37 $
Mkt. cap
85,30 млн
Avg. vol.
1,21 млн
Volume
0,00
52-wk high
20,56 $
52-wk low
4,37 $
EPS
-6,17 $
Beta
2,63
Shares outstanding
19,34 млн
No. of employees
36
News stories
From web sources and news partners
About Corbus Pharmaceuticals Holdings Inc
CEO-
Employees36
Founded2009 ж. 01 қаң.
Headquarters-
Sector-
Websitecorbuspharma.com
Analyst ratings
Based on 7 analysts giving stock ratings to CRBP in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for CRBP in the last 3 months.
Highest
Current 4,41 $
48,00 $ (+988,44%)
Average
36,67 $ (+731,52%)
Lowest
30,00 $ (+580,27%)
Analyst
Recommendation
Action
Price target
Projected
Date
Robert Driscoll
Wedbush
Buy
Reiterated
30,00 $
+580,3%
09/15/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Reiterated
35,00 $
+693,7%
09/15/2026
Andy Hsieh
William Blair
Buy
Reiterated
-
-
09/14/2026
Oliver McCammon
LifeSci Capital
Buy
Maintained
38,00 $
+761,7%
09/14/2026
Graig Suvannavejh
Mizuho Securities
Buy
Reiterated
33,00 $
+648,3%
09/14/2026
Brian Abrahams
RBC Capital
Buy
Maintained
36,00 $
+716,3%
08/12/2026
Jeff Jones
Oppenheimer
Buy
Reiterated
48,00 $
+988,4%
08/07/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
48,00 $
+988,4%
08/07/2026
Paul Jeng
Guggenheim
Buy
Maintained
45,00 $
+920,4%
06/02/2026
Unknown Analyst
Wedbush
Buy
Reiterated
38,00 $
+761,7%
05/13/2026
Maury Raycroft
Jefferies
Buy
Maintained
33,00 $
+648,3%
05/12/2026
Unknown Analyst
B. Riley Securities
Buy
Reiterated
28,00 $
+534,9%
04/10/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
-
-
-
-
Cost of goods sold
20,86 млн
18,41 млн
19,82 млн
31,18 млн
Cost of revenue
20,86 млн
18,41 млн
19,82 млн
31,18 млн
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,56 млн
3,56 млн
4,48 млн
5,02 млн
Operating expense
3,56 млн
3,56 млн
4,48 млн
5,02 млн
Total operating expenses
24,42 млн
21,97 млн
24,30 млн
36,19 млн
Operating income
-24,42 млн
-21,97 млн
-24,30 млн
-36,19 млн
Other non operating income
-50,00 мың
-1,10 млн
-67,00 мың
-11,00 мың
EBT including unusual items
-23,34 млн
-20,56 млн
-22,97 млн
-35,04 млн
EBT excluding unusual items
-23,34 млн
-21,66 млн
-22,97 млн
-35,04 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-23,34 млн
-20,56 млн
-22,97 млн
-35,04 млн
Net profit margin
-
-
-
-
Earnings per share
-1,90
-1,25
-1,23
-1,81
Interest and investment income
1,12 млн
1,41 млн
1,40 млн
1,16 млн
Interest expense
-
-
-
-
Net interest expenses
1,12 млн
1,41 млн
1,40 млн
1,16 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-24,37 млн
-21,92 млн
-24,26 млн
-36,14 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google қолданбалары